According to the SEC Form 4 filing on June 26, 2025, Jerrell Shelton, president and CEO, exercised $5 per share options on 16,344 shares of Cryoport(CYRX 1.89%) and proceeded to sell them at $7.0586 per share (on average) on June 24, 2025, for a total sale price of $115,365.
Transaction summary
| Metric | Value | Context |
|---|---|---|
| Transaction size | 16,344 shares (~$115,365) | Form 4 filed June 26, 2025; option exercise and sale |
| Post-transaction position | 928,763 shares (~$6.77 million) | 1.85% ownership as of June 26, 2025 |
| Option price vs 50-day MA | $5.00 vs $6.29 | 20.5% below 50-day moving average (as of June 27, 2025) |
| Option price vs 200-day MA | $5.00 vs $6.96 | 28.2% below 200-day moving average (as of June 27, 2025) |
| YTD performance | 1.9% | Price change as of June 30, 2025 |
Key questions
- How does this transaction compare to the insider’s historical trading patterns?
The exercise and sale of 16,344 shares is below Jerrell Shelton's historical median transaction size of 50,000 shares and the 75th percentile value of 158,829 shares, with an average of 7.4 trades per year and a 23.5% rate of option-related transactions. - What is the significance of the transaction price relative to market averages?
The option price of $5 per share is 20.5% below the 50-day moving average and 28.2% below the 200-day moving average, reflecting typical option exercise pricing rather than a market sale. - How does this transaction impact the insider’s ownership and alignment?
After the transaction, Jerrell Shelton retains 928,763 shares, representing a 1.85% ownership stake and a market value of approximately $6.77 million, maintaining significant alignment with shareholders. - What is the context of timing for this trade?
This transaction follows a pattern of frequent trading by insiders, with the previous gap between trades at six days, consistent with the insider’s high annual activity rate and regular participation in option exercises.
Company overview
| Company Data | Market Data |
|---|---|
| Revenue (2024): $228.39 million | Current price: $7.94 |
| Net income loss (2024): $114.76 million | Dividend yield: 0.0% |
| Employees: 1,090 | 50-day moving average: $6.29 |
| One-year stock price change: 14.8% | 200-day moving average: $6.96 |
Company snapshot
- Provides temperature-controlled logistics solutions, cloud-based logistics management, cryogenic shippers, and specimen storage services for life sciences applications.
- Generates revenue through the provision of logistics management, transportation, storage, and consulting services for biologic commodities and specimens.
- Serves biopharma, pharmaceutical, animal health, and human reproductive medicine clients across the Americas, EMEA, and Asia Pacific regions.
Cryoport is a specialized provider of temperature-controlled logistics and storage solutions for the life sciences sector, supporting the global movement and preservation of sensitive biological materials. The company leverages proprietary technology and cloud-based platforms to ensure regulatory compliance and shipment integrity for its clients.
Foolish take
While I'm not a fan of following top insiders' actions when they buy or sell their own stock, I think I'd follow Shelton here if I were a Cryoport stockholder and unload my holdings.
While the company operates an interesting business at the intersection of healthcare and logistics, its recent performance is not overly impressive. Cryoport has seen drops in revenue in recent quarters and has posted losses that have been rather deep at times. Meanwhile, there haven't been any developments lately suggesting any kind of meaningful reversal in its financial trajectory is in the works.
Earlier this month, the company completed the sale of its CryoPDP specialty courier business to global logistics king DHL Group (DHLG.Y -0.98%). While this slims Cryoport some and provides a bit of a cash infusion from the divestment, I don't think it'll tip Cryoport stock into buy territory on its own. I wouldn't be a buyer of the company's shares, at least until some clearer signs of potential improvement emerge.
Glossary
SEC Form 4: A regulatory filing showing insider trades of company stock by officers, directors, or major shareholders.
Insider trading: Buying or selling a company's securities by its executives, directors, or significant shareholders.
Option exercise: When an individual uses their right to buy company shares at a set price through stock options.
Moving average (MA50, MA200): The average stock price over the past 50 or 200 days, used to identify trends.
Ownership stake: Trades involving the exercise or sale of stock options, not direct market purchases or sales.
Post-transaction position: The number of shares an insider holds after completing a trade.
Dividend yield: The annual dividend payment divided by the stock price, shown as a percentage.
Biologic commodities: Biological materials, such as cells or tissues, used in medical or scientific applications.
Regulatory compliance: Adhering to laws and regulations relevant to a company's industry or activities.
Specimen storage: The secure holding of biological samples under controlled conditions for future use.
Cloud-based logistics management: Using online platforms to track and manage the movement and storage of goods.
